Literature DB >> 16406434

Imaging liver metastases: review and update.

Masayuki Kanematsu1, Hiroshi Kondo, Satoshi Goshima, Hiroki Kato, Usuke Tsuge, Yoshinobu Hirose, Myeong-Jin Kim, Noriyuki Moriyama.   

Abstract

The radiologic diagnosis of liver metastasis involves detection, characterization, and tumor staging. Knowledge of the histopathologic changes that occur with metastases provides the best approach to the accurate interpretation of radiologic imaging findings, and in particular, radiologists need to choose appropriate imaging methods based on such knowledge. Because the majority of metastases are hypovascular, the merits of the routine acquisition of hepatic arterial dominant-phase images by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) are disputable. Hepatic arterial dominant-phase images may be obtained when hypervascular tumors are suspected or three-dimensional CT angiography is necessary. And, imaging during the portal venous phase is essential for detecting metastases, evaluating intrahepatic vessel invasion, and for assessing intratumoral necrosis or fibrosis. Equilibrium- to delayed-phase imaging 3-5 min after contrast administration may improve the detection of intratumoral fibrosis, and occasionally lead to more accurate tissue characterization. MRI offers diagnostic information on vascularity, amount of free water, hemorrhage, fibrosis, necrosis, and water molecule diffusion in metastases. And, liver-specific contrast agents like superparamagnetic iron oxide, liposoluble gadolinium chelate, and manganese may improve the MRI-based diagnosis of liver metastases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406434     DOI: 10.1016/j.ejrad.2005.11.041

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  21 in total

1.  Characterisation of small hypoattenuating hepatic lesions in multi-detector CT (MDCT) in patients with underlying extrahepatic malignancy: added value of contrast-enhanced MR images.

Authors:  Song-Ee Baek; Mi-Suk Park; Hye Sook Hong; Jin Young Choi; Yong Eun Chung; Joon Seok Lim; Myeong-Jin Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2010-07-09       Impact factor: 5.315

Review 2.  Differentiation of hepatocellular carcinoma from its various mimickers in liver magnetic resonance imaging: What are the tips when using hepatocyte-specific agents?

Authors:  Yang Shin Park; Chang Hee Lee; Jeong Woo Kim; Sora Shin; Cheol Min Park
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Emerging roles for integrated imaging modalities in cardiovascular cell-based therapeutics: a clinical perspective.

Authors:  Peter J Psaltis; Robert D Simari; Martin Rodriguez-Porcel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-08       Impact factor: 9.236

4.  Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.

Authors:  Ling Zhang; Xian Yu; Lei Huo; Lun Lu; Xinpeng Pan; Ningyang Jia; Xinxiang Fan; Giovanni Morana; Luigi Grazioli; Guenther Schneider
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

Review 5.  Imaging of Colorectal Liver Metastasis.

Authors:  Azarakhsh Baghdadi; Sahar Mirpour; Maryam Ghadimi; Mina Motaghi; Bita Hazhirkarzar; Timothy M Pawlik; Ihab R Kamel
Journal:  J Gastrointest Surg       Date:  2021-10-18       Impact factor: 3.452

6.  Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent.

Authors:  Peter Reimer; Rolf Vosshenrich
Journal:  Biologics       Date:  2010-08-09

7.  [Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].

Authors:  A Heidenreich; S Krege
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

8.  Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer.

Authors:  A Gines; S D Cassivi; J A Martenson; C Schleck; C Deschamps; F A Sinicrope; S R Alberts; J A Murray; Alan R Zinsmeister; Enrique Vazquez-Sequeiros; F C Nichols; R C Miller; J F Quevedo; M S Allen; J A Alexander; T Zais; M G Haddock; Y Romero
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

Review 9.  [Computed tomography and/or magnetic resonance imaging of the liver : How, why, what for?]

Authors:  G H Pöhler; K I Ringe
Journal:  Radiologe       Date:  2019-09       Impact factor: 0.635

10.  [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.

Authors:  Christopher Cawthorne; Natalie Burrows; Roben G Gieling; Christopher J Morrow; Duncan Forster; Jamil Gregory; Marc Radigois; Alison Smigova; Muhammad Babur; Kathryn Simpson; Cassandra Hodgkinson; Gavin Brown; Adam McMahon; Caroline Dive; Duncan Hiscock; Ian Wilson; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.